Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Acumen Pharmaceuticals Announces First Close of Series A Financing

Published: Monday, April 29, 2013
Last Updated: Monday, April 29, 2013
Bookmark and Share
Proceeds will fund lead-drug candidate ACU-193 to proof of concept in Alzheimer’s disease.

Acumen Pharmaceuticals, Inc., has announced that it has completed a first closing of a $20 million Series A financing led by BVF Partners L.P. (BVF), a leading life sciences investment firm which manages the Biotechnology Value Fund, L.P. NeuroVentures Fund, L.P., Praxis Technologies, Glynn Ventures and private investors also participated in the closing.

Acumen will use the Series A proceeds to fund preclinical and potentially early clinical development of ACU-193, a monoclonal antibody that selectively binds to and captures soluble oligomers of the amyloid-beta peptide.

ACU-193 could demonstrate clinical proof of concept in Alzheimer’s disease by 2016.

Alzheimer’s disease and related degenerative disorders of the aging brain represent one of the largest and most significant unmet medical needs of modern societies.

“ACU-193 represents a distinct and promising drug candidate for Alzheimer’s disease”, said Franz F. Hefti, PhD., CEO of Acumen. “Acumen recently presented its focused development program to the FDA in a pre-IND meeting, and the rationale for ACU-193 and an anti-oligomer approach has been summarized in a special publication, which appeared this month in the leading review journal Trends in Pharmacological Sciences”.

ACU-193 is a potential first in class molecule, expected to be effective as a standalone therapy or in combination with other Alzheimer drugs.

ACU-193 selectively captures soluble oligomers of amyloid-beta, and thus has a different mechanism of action from bapineuzumab and other anti-amyloid antibodies.

Soluble oligomers of amyloid-beta are now recognized widely as key pathogenic structures in Alzheimer’s disease.

These oligomers bind to and inhibit the function of nerve cells, leading to early memory deficits, and trigger downstream events such as amyloid plaques and tau pathology.

ACU-193 is expected to achieve rapid symptomatic clinical benefit in patients with Alzheimer’s disease because memory performance should improve upon the removal of soluble oligomers by ACU-193. Acumen is planning a Phase I/IIa clinical study design to demonstrate clinical proof of concept.

“BVF has participated in funding Acumen Pharmaceuticals and has followed the programs with enthusiasm from the very beginning”, said Mark Lampert, Founder of BVF.

Lampert continued, “We are delighted to lead the financing of ACU-193. It is a privilege to help bring this exceptionally promising medication to patients suffering from Alzheimer’s disease.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More Than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Microdroplet Reactors Mimic Living Systems
Researchers use microdroplets to study non-equilibrium reactions like those in living organisms.
NIH Researchers Identify Striking Genomic Signature for Cancer
Institute has identified striking signature shared by five types of cancer.
CRI Develops Innovative Approach for Identifying Lung Cancer
Institute has developed innovative approach for identifying processes that fuel tumor growth in lung cancer patients.
Envigo Rat Models Proven to be Susceptible to Intra-Vaginal HSV-2 Infection and Protectable
Scientific findings establish the effectiveness of new approach to investigate the protective effects of vaccine candidates and anti-viral microbodies and to study asymptomatic primary genital HSV-2 infection.
What do Banana Peels and Human Skin Have in Common?
Human skin and banana peels have something in common: they produce the same enzyme when attacked. By studying fruit, researchers have come up with an accurate method for diagnosing the stages of this form of skin cancer.
The Spice of Life
Scientists discover important genetic source of human diversity.
Cytoskeleton Crew
Findings confirm sugar's role in helping cancers survive by changing cellular architecture.
The Power of Three
Overlooked portion of cell “death receptor” critical in some cancers, autoimmune diseases.
Drug that Activates Innate Immune System Identified
Researchers from the institute have identified a drug, which is straightforward to synthesize and to couple to antigens that induce an immune response and may prove useful in the generation of vaccines.
Removing Race from Human Genetic Research
A group of scientists are urging their colleagues to take a step forward and stop using racial categories when researching and studying human genetics.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!